Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (121-130 of 436) with videos related to

Pageof 44
Sort By:
Health Affairs (Project Hope)|February 4, 2015
The roles of academia, rare diseases, and repurposing in the development of the most transformative drugsAaron S Kesselheim, Yongtian Tina Tan, Jerry Avorn
The Milbank Quarterly|December 3, 2015
Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative StudyCarolyn L Treasure, Jerry Avorn, Aaron S Kesselheim
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillationAmanda R Patrick, Jerry Avorn, Niteesh K Choudhry
Journal of the American Geriatrics Society|October 4, 2007
Quality indicators for medication use in vulnerable eldersWilliam H Shrank, Jennifer M Polinski, Jerry Avorn
The New England Journal of Medicine|April 12, 2018
The FDA Breakthrough-Drug Designation - Four Years of ExperienceJonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|May 4, 2017
The Failure of Solanezumab - How the FDA Saved Taxpayers BillionsChana A Sacks, Jerry Avorn, Aaron S Kesselheim
Health Affairs (Project Hope)|November 15, 2006
Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spendingAaron S Kesselheim, Michael A Fischer, Jerry Avorn
The New England Journal of Medicine|March 28, 2014
New FDA breakthrough-drug category--implications for patientsJonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|May 18, 2022
Institutionalizing Misinformation - The Dietary Supplement Listing Act of 2022Pieter A Cohen, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine|December 3, 2019
Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined FormularyWilliam B Feldman, Jerry Avorn, Aaron S Kesselheim
Pageof 44

Showing results (121-130 of 436) with videos related to

Sort By:
Pageof 44
Health Affairs (Project Hope)|February 4, 2015
The roles of academia, rare diseases, and repurposing in the development of the most transformative drugsAaron S Kesselheim, Yongtian Tina Tan, Jerry Avorn
The Milbank Quarterly|December 3, 2015
Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative StudyCarolyn L Treasure, Jerry Avorn, Aaron S Kesselheim
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillationAmanda R Patrick, Jerry Avorn, Niteesh K Choudhry
Journal of the American Geriatrics Society|October 4, 2007
Quality indicators for medication use in vulnerable eldersWilliam H Shrank, Jennifer M Polinski, Jerry Avorn
The New England Journal of Medicine|April 12, 2018
The FDA Breakthrough-Drug Designation - Four Years of ExperienceJonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|May 4, 2017
The Failure of Solanezumab - How the FDA Saved Taxpayers BillionsChana A Sacks, Jerry Avorn, Aaron S Kesselheim
Health Affairs (Project Hope)|November 15, 2006
Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spendingAaron S Kesselheim, Michael A Fischer, Jerry Avorn
The New England Journal of Medicine|March 28, 2014
New FDA breakthrough-drug category--implications for patientsJonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|May 18, 2022
Institutionalizing Misinformation - The Dietary Supplement Listing Act of 2022Pieter A Cohen, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine|December 3, 2019
Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined FormularyWilliam B Feldman, Jerry Avorn, Aaron S Kesselheim
Pageof 44